RESUMO
<p><b>OBJECTIVE</b>To explore the feasibility and safety of scarless laparoscopic radical resection of rectal cancer.</p><p><b>METHODS</b>Clinical data of 26 patients who underwent scarless laparoscopic radical resection of rectal cancer from January 2011 to June 2013 were retrospectively analyzed. Lymph node dissection and transection of proximal and distal colon were performed in the conventional manner of total mesorectal excision (TME). The distal rectum 2 cm away from the tumor was closed with a linear stapler, and was pulled out through the anus. The specimen was extracted through the Alexis. The rectal opening was reclosed with a linear stapler. End-to-end colorectal anastomosis was performed using the double-stapling technique.</p><p><b>RESULTS</b>The operation time was (126±35) min. The intraoperative blood loss was (33±61) ml. The number of harvested lymph nodes was 17.0±5.6. The time to first bowel movement was (2.7±1.3) d. The postoperative hospital stay was (7.9±2.6) d. Only one case developed anastomotic hemorrhage.</p><p><b>CONCLUSION</b>Scarless laparoscopic radical resection of rectal cancer is feasible.</p>
Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Anastomose Cirúrgica , Métodos , Laparoscopia , Métodos , Excisão de Linfonodo , Neoplasias Retais , Cirurgia Geral , Estudos RetrospectivosRESUMO
Objective To investigate the effect of binding pancreaticojejunostomy (BPJ) on the prevention of the pancreatic leakage after pancreaticoduodenectomy(PD). Methods The clinical data of 108 patients who underwent PD, including 26 cases of BPJ since 2001 and 82 cases of other type of pancreaticojejunostomy from 1993 to 2000,were retrospectively analyzed. Results The frequency of pancreatic leakage in this series was 13.9%. No pancreatic leakage occurred in BPJ group, whereas the frequency of pancreatic leakage in end-to-end invaginated pancreaticojejunostomy group and duct-to-mucosa pancreaticojejunostomy group was 24.6%(14/57) and 4.0%(1/25),respectively. The frequency of pancreatic leakage in BPJ group was significantly lower than that in end-to-end invaginated pancreaticojejunostomy group(P0.05). Conclusion BPJ may be effective in the prevention of the pancreatic leakage after PD.
RESUMO
Objective Effects of intra articular injection of 153 Sm citrate HA on antigen induced arthritis were investigated to provide the theoretical fundation for its clinical application.Methods Rabbit arthritis was induced by subcutaneous injection of ovalbumin at weeks 2 and 4,and by intra articular injection of it at week 6.The dosage of 1 85?10 7 Bq or 3 7?10 7 Bq of 153 Sm citrate HA was injected separately into a side of knee joint.The severity of arthritis was determined by joint swelling,skin surface temperature,macroscopic and histologic changes in joints when the rabbits were killed at week 9 after establishment of model.Results Both dosages of 153 Sm have an initial pro inflammatory effects during one week after injection,and then resulted in reduction of joint diameter and skin surface temperature. 153 Sm (3 7?10 7 Bq) showed a more alleviation than 153 Sm (1 85?10 7 Bq) in respect of macroscopic and histologic changes.Conclusion Synovectomy with 153 Sm citrate HA is effective for treatment of chronic arthritis with dependence on the doses and deserves further study.
RESUMO
In this study, pancreatic tissue carcinoma antigen (PCA) was extracted from human pancreatic adenocarcinoma tissue, partially purified by chromatography, and confirmed by immunological methods. It was demonstrated by immunofluore-scence technique thatPCA resided in the cytoplasm and plasma membrane of pancreatic carcinoma cells. The specific antisera against PCA was acquired from immunized rabbits. The antiPCA antibody had specificity to sera with pancreatic carcinoma cells. We established ELISA for determination of PCA, and detected 233 cases of pancreatic carcinoma, alimentary cancer and alimentary benign disease with ELISA. It is indicated that PCA is clearly different from other tumor markers such as PCA, CEA and POA, and is a new tumor marker specific to pancreatic carcinoma.